← Back to Search

Wee1 Inhibitor

ZN-d5 + ZN-c3 for Acute Myeloid Leukemia

Q: What is the total enrollment of this medical experiment?

<p>Affirmative. The clinicaltrials.gov portal verifies that the trial, whose initial posting was on December 1st 2022, is presently recruiting participants. 95 volunteers need to be enrolled from 3 distinct medical departments.</p>

Q: Are there any openings left for individuals to join this research endeavor?

<p>Affirmative. According to the information accessible on clinicaltrials.gov, this medical experiment is actively enrolling participants from its initial posting date of December 1st 2022 and most recent update of January 3rd 2023. The trial necessitates 95 patients over three different sites.</p>

Phase 1 & 2

Recruiting

Research Sponsored by K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, typically <12 months

Awards & highlights

Study Summary

This trial is testing new drugs to treat AML, a type of blood cancer.

Who is the study for?

Adults with Acute Myeloid Leukemia (AML) who have not responded well to previous treatments can join this trial. They should be relatively stable (ECOG ≤2), expected to live at least 12 weeks, and have good kidney function. Women must use birth control, and men must use condoms during the study and for some time after.Check my eligibility

What is being tested?

The trial is testing two drugs: ZN-d5, a BCL-2 inhibitor, and ZN-c3, a Wee1 inhibitor. It's in phases 1/2 which means they're looking at what doses are safe (phase 1) and how effective these drugs are (phase 2) in treating AML.See study design

What are the potential side effects?

Possible side effects of ZN-d5 and ZN-c3 may include changes in blood counts leading to increased risk of infections or bleeding, fatigue, nausea or vomiting. There might also be liver-related issues or reactions related to drug infusion.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, typically <12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, typically <12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, typically <12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Incidence, severity, and relatedness of adverse events( AEs)

Observed dose limiting toxicities

Secondary outcome measures

1. To investigate the plasma PK of ZN-c3 when given as monotherapy - Maximum Plasma Concentration

2. To investigate the plasma PK of ZN-c3 when given as monotherapy - Area under the plasma concentration-time curve from 0 to 24h

5. To investigate the plasma PK of ZN-c3 and ZN-d5 when given in combination - Maximum Plasma Concentration

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Acute Myeloid LeukemiaExperimental Treatment2 Interventions

Phase 1: Dose Escalation- c3 monotherapy and d5+c3 combination Phase 2: Dose Expansion

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.Lead Sponsor

3 Previous Clinical Trials

266 Total Patients Enrolled

K-Group Alpha, Inc. a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.Study DirectorK-Group Alpha

Media Library

ZN-c3 (Wee1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05682170 — Phase 1 & 2

Acute Myeloid Leukemia Research Study Groups: Acute Myeloid Leukemia

Acute Myeloid Leukemia Clinical Trial 2023: ZN-c3 Highlights & Side Effects. Trial Name: NCT05682170 — Phase 1 & 2

ZN-c3 (Wee1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05682170 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the total enrollment of this medical experiment?

"Affirmative. The clinicaltrials.gov portal verifies that the trial, whose initial posting was on December 1st 2022, is presently recruiting participants. 95 volunteers need to be enrolled from 3 distinct medical departments."

Answered by AI

Are there any openings left for individuals to join this research endeavor?

"Affirmative. According to the information accessible on clinicaltrials.gov, this medical experiment is actively enrolling participants from its initial posting date of December 1st 2022 and most recent update of January 3rd 2023. The trial necessitates 95 patients over three different sites."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

2022. "Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05682170.